Abstract
The loss-of-function mechanism in progranulin (PGRN) mutation carriers makes PGRN an interesting target for upregulation as a therapeutic approach in neurodegenerative diseases like frontotemporal lobar degeneration. This gives rise to several questions: (1) how stable are PGRN levels in blood and cerebrospinal fluid (CSF) in follow-up? (2) Is it necessary to measure PGRN levels in CSF to monitor a therapeutic effect? Therefore, concentrations of PGRN were measured in paired CSF and serum samples of 22 patients with behavioural variant frontotemporal dementia, including one GRN mutation carrier (c.349+1G>C), 16 patients with amyotrophic lateral sclerosis and 17 non-neurodegenerative patients, which included 22 follow-up levels. PGRN levels of 14 patients with isolated dysfunction of the blood-CSF barrier were measured and PGRN was correlated with albumin quotients as a marker for blood-CSF barrier function. The intrathecal fraction of PGRN was calculated on the basis of CSF-to-serum ratios and hydrodynamic properties. Follow-up measurements of CSF and serum PGRN levels did not show any significant change in diagnostic groups. Mean PGRN levels are 35 times higher in blood than in CSF. However, the CSF-to-serum PGRN ratio does not correlate with the albumin quotient even in patients with severe impairment of the blood-CSF barrier. The calculated intrathecal fraction of CSF PGRN levels ranged between 80 and 90 %. Assuming that CSF PGRN is either brain-derived or transported from the vascular compartment via receptor mediated mechanisms, we propose that monitoring CNS specific effects of PGRN modulating drugs should be done in CSF.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alberici A, Archetti S, Pilotto A, Premi E, Cosseddu M, Bianchetti A, Semeraro F, Salvetti M, Muiesan ML, Padovani A, Borroni B (2014) Results from a pilot study on amiodarone administration in monogenic frontotemporal dementia with granulin mutation. Neurol Sci 35(8):1215–1219. doi:10.1007/s10072-014-1683-y
Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm C, Snowden J, Adamson J, Sadovnick AD, Rollinson S, Cannon A, Dwosh E, Neary D, Melquist S, Richardson A, Dickson D, Berger Z, Eriksen J, Robinson T, Zehr C, Dickey CA, Crook R, McGowan E, Mann D, Boeve B, Feldman H, Hutton M (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442(7105):916–919. doi:10.1038/nature05016
Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293–299
Cain SA, McGovern A, Small E, Ward LJ, Baldock C, Shuttleworth A, Kielty CM (2009) Defining elastic fiber interactions by molecular fishing: an affinity purification and mass spectrometry approach. Mol Cell Proteomics 8(12):2715–2732. doi:10.1074/mcp.M900008-MCP200
Capell A, Liebscher S, Fellerer K, Brouwers N, Willem M, Lammich S, Gijselinck I, Bittner T, Carlson AM, Sasse F, Kunze B, Steinmetz H, Jansen R, Dormann D, Sleegers K, Cruts M, Herms J, Van Broeckhoven C, Haass C (2011) Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J Neurosci 31(5):1885–1894. doi:10.1523/JNEUROSCI.5757-10.2011
Cenik B, Sephton CF, Dewey CM, Xian X, Wei S, Yu K, Niu W, Coppola G, Coughlin SE, Lee SE, Dries DR, Almeida S, Geschwind DH, Gao FB, Miller BL, Farese RV Jr, Posner BA, Yu G, Herz J (2011) Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J Biol Chem 286(18):16101–16108. doi:10.1074/jbc.M110.193433
Felgenhauer K (1974) Protein size and cerebrospinal fluid composition. Klin Wochenschr 52(24):1158–1164
Feneberg E, Steinacker P, Lehnert S, Schneider A, Walther P, Thal DR, Linsenmeier M, Ludolph AC, Otto M (2014) Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph Lateral Scler Frontotemporal Degener 15(5–6):351–356. doi:10.3109/21678421.2014.905606
Finch N, Baker M, Crook R, Swanson K, Kuntz K, Surtees R, Bisceglio G, Rovelet-Lecrux A, Boeve B, Petersen RC, Dickson DW, Younkin SG, Deramecourt V, Crook J, Graff-Radford NR, Rademakers R (2009) Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 132(Pt 3):583–591. doi:10.1093/brain/awn352
Galimberti D, Bonsi R, Fenoglio C, Serpente M, Cioffi SM, Fumagalli G, Arighi A, Ghezzi L, Arcaro M, Mercurio M, Rotondo E, Scarpini E (2015) Inflammatory molecules in Frontotemporal Dementia: cerebrospinal fluid signature of progranulin mutation carriers. Brain Behav Immun 49:182–187. doi:10.1016/j.bbi.2015.05.006
Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G (2008) Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 71(16):1235–1239. doi:10.1212/01.wnl.0000325058.10218.fc
He Z, Bateman A (1999) Progranulin gene expression regulates epithelial cell growth and promotes tumor growth in vivo. Cancer Res 59(13):3222–3229
Jesse S, Brettschneider J, Sussmuth SD, Landwehrmeyer BG, von Arnim CA, Ludolph AC, Tumani H, Otto M (2011) Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. J Neurol 258(6):1034–1041. doi:10.1007/s00415-010-5876-x
Kleinberger G, Wils H, Ponsaerts P, Joris G, Timmermans JP, Van Broeckhoven C, Kumar-Singh S (2010) Increased caspase activation and decreased TDP-43 solubility in progranulin knockout cortical cultures. J Neurochem 115(3):735–747. doi:10.1111/j.1471-4159.2010.06961.x
Kumar-Singh S (2011) Progranulin and TDP-43: mechanistic links and future directions. J Mol Neurosci 45(3):561–573. doi:10.1007/s12031-011-9625-0
Mackenzie IR, Baker M, Pickering-Brown S, Hsiung GY, Lindholm C, Dwosh E, Gass J, Cannon A, Rademakers R, Hutton M, Feldman HH (2006) The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 129(Pt 11):3081–3090. doi:10.1093/brain/awl271
Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, Perry RH, Trojanowski JQ, Mann DM, Lee VM (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 122(1):111–113. doi:10.1007/s00401-011-0845-8
Minami SS, Shen V, Le D, Krabbe G, Asgarov R, Perez-Celajes L, Lee CH, Li J, Donnelly-Roberts D, Gan L (2015) Reducing inflammation and rescuing FTD-related behavioral deficits in progranulin-deficient mice with alpha7 nicotinic acetylcholine receptor agonists. Biochem Pharmacol 97(4):454–462. doi:10.1016/j.bcp.2015.07.016
Mohanty AK, Wiener MC (2004) Membrane protein expression and production: effects of polyhistidine tag length and position. Protein Expr Purif 33(2):311–325
Nicholson AM, Finch NA, Thomas CS, Wojtas A, Rutherford NJ, Mielke MM, Roberts RO, Boeve BF, Knopman DS, Petersen RC, Rademakers R (2014) Progranulin protein levels are differently regulated in plasma and CSF. Neurology 82(21):1871–1878. doi:10.1212/WNL.0000000000000445
Philips T, De Muynck L, Thu HN, Weynants B, Vanacker P, Dhondt J, Sleegers K, Schelhaas HJ, Verbeek M, Vandenberghe R, Sciot R, Van Broeckhoven C, Lambrechts D, Van Leuven F, Van Den Bosch L, Robberecht W, Van Damme P (2010) Microglial upregulation of progranulin as a marker of motor neuron degeneration. J Neuropathol Exp Neurol 69(12):1191–1200. doi:10.1097/NEN.0b013e3181fc9aea
Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134(Pt 9):2456–2477. doi:10.1093/brain/awr179
Reiber H (1983) Kinetics of protein agglomeration. A nephelometric method for the determination of total protein in biological samples. J Biochem Biophys Methods 7(2):153–160
Reiber H (1994) Flow rate of cerebrospinal fluid (CSF)—a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci 122(2):189–203
Snowden JS, Pickering-Brown SM, Mackenzie IR, Richardson AM, Varma A, Neary D, Mann DM (2006) Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia. Brain 129(Pt 11):3091–3102. doi:10.1093/brain/awl267
Ungurs MJ, Sinden NJ, Stockley RA (2014) Progranulin is a substrate for neutrophil-elastase and proteinase-3 in the airway and its concentration correlates with mediators of airway inflammation in COPD. Am J Physiol Lung Cell Mol Physiol 306(1):L80–L87. doi:10.1152/ajplung.00221.2013
Van Damme P, Van Hoecke A, Lambrechts D, Vanacker P, Bogaert E, van Swieten J, Carmeliet P, Van Den Bosch L, Robberecht W (2008) Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol 181(1):37–41. doi:10.1083/jcb.200712039
Vercellino M, Grifoni S, Romagnolo A, Masera S, Mattioda A, Trebini C, Chiavazza C, Caligiana L, Capello E, Mancardi GL, Giobbe D, Mutani R, Giordana MT, Cavalla P (2011) Progranulin expression in brain tissue and cerebrospinal fluid levels in multiple sclerosis. Mult Scler 17(10):1194–1201. doi:10.1177/1352458511406164
Widl K, Brettschneider J, Schattauer D, Sussmuth S, Huber R, Ludolph AC, Tumani H (2007) Erythropoietin in cerebrospinal fluid: age-related reference values and relevance in neurological disease. Neurochem Res 32(7):1163–1168. doi:10.1007/s11064-007-9286-0
Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, Lacomis L, Erdjument-Bromage H, Tempst P, Wright CD, Ding A (2002) Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 111(6):867–878
Acknowledgments
This work was supported by BMBF (Federal Ministry of Education and Research, Germany): Competence net neurodegenerative dementias (project: FTLDc), the MND-net, the JNPD networks for standardization of biomarkers (BiomarkAPD, Sophia), the EU (NADINE), foundation of the state of Baden-Württemberg, BWMi (Federal ministry for Economic Affairs and Energy) and BIU.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Feneberg, E., Steinacker, P., Volk, A.E. et al. Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD. J Neural Transm 123, 289–296 (2016). https://doi.org/10.1007/s00702-015-1486-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-015-1486-1